Phil Hornick

Phil Hornick, MD, PhD has an extensive work history in the pharmaceutical industry. Phil served as the SVP and Head of Global Medical at Ultragenyx Pharmaceutical Inc. since 2019. Before that, they held various roles at GSK, including VP & Therapeutic Area Head for Specialty, Rare Disease, & Established Medicines, Medical Affairs from 2015 to 2019. Phil also worked at Forest Laboratories as VP & Therapeutic Area Head for CV and Metabolic, Global Clinical Development and Medical Affairs from 2012 to 2014. Prior to that, they were with Bristol-Myers Squibb, where they held positions such as Executive Director, Cardiovascular, Global and US Medical Affairs from 2010 to 2012.

Phil Hornick, MD, PhD has a diverse education history that includes studying at various prestigious institutions. Phil attended the University of Cambridge and Imperial College London, although the specific degree and field of study are not mentioned. Phil also studied at The Royal London Hospital and the Royal College of Surgeons England, but again, no degree or field of study is provided. Additionally, they completed a sabbatical at Harvard Medical School - Massachusetts General Hospital. In terms of specialized education, they worked as a Senior Visiting Fellow in Cardiac Surgery and Transplantation at St Vincent's Hospital Sydney. Furthermore, they completed executive courses in Marketing and Pharmaceutical Executive Management at The Wharton School.